@Article{Kramza2011,
journal="Reumatologia/Rheumatology",
issn="0034-6233",
volume="49",
number="4",
year="2011",
title="Application of biological agents for treatment of patients with systemic lupus erythematosus",
abstract="Systemic lupus erythematosus is an autoimmune disorder of unknown aetiology. High efficacy of biological agents in patients with rheumatoid arthritis suggests investigations on similar medication applicable in the management of systemic lupus erythematosus. Several antibodies were investigated including those against soluble B-lymphocyte-stimulating factor, BLyS (B lymphocyte stimulator) (belimubab, briobacept, atacicept), against B cells (rituximab, ocrelizumab, epratuzumab), inhibiting co-stimulation of T cells (abatacept), tolerogens, interferon and others. Despite some beneficial effects, none of the investigated agents is recommended for clinical practice.",
author="Kramza, Justyna
and J. Kucharz, Eugeniusz",
pages="264--274",
url="https://www.termedia.pl/Application-of-biological-agents-for-treatment-of-patients-with-systemic-lupus-erythematosus-,18,17173,1,1.html"
}